Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Table 1 Baseline demographics and patient characteristics

Characteristic	CZP ITT population (n = 492)	Week 24 CZP completers (n = 342)	Week 24 placebo completers (n = 17)	Dose-reduction population (n = 369)	Safety population (n = 612)
Age, mean (SD), years	52.0 (11.4)	51.6 (11.6)	53.2 (16.0)	51.1 (11.3)	51.9 (11.5)
Gender, % female	80.9	82.7	82.4	81.8	81.5
Disease duration, mean (SD), years	6.3 (4.2)	6.5 (4.2)	3.5 (2.3)	6.2 (4.2)	6.2 (4.2)
RF-positive (≥14 IU/ml), %	76.5	75.4	88.2	73.7	76.9
Tender/painful joint count, mean (SD)	30.1 (14.2)	30.5 (14.5)	33.4 (12.1)	29.9 (13.9)	30.2 (14.0)
Swollen joint count, mean (SD)	20.7 (9.9)	20.7 (10.1)	24.2 (8.2)	20.6 (10.1)	21.0 (9.9)
Pain VAS, mean (SD)	61.2 (19.7)	60.6 (19.8)^a	59.1 (21.6)	61.2 (19.5)^b	60.9 (20.3)^c
HAQ-DI, mean (SD)	1.6 (0.6)	1.6 (0.6)	1.6 (0.5)	1.6(0.6)	1.6 (0.6)^d
DAS28(ESR), median (min, max)	6.8 (4, 9)^e	6.8 (5, 9)^a	7.1 (6, 8)	6.8 (5, 9)^b	6.9 (4, 9)^f

^an = 340; ^bn = 367; ^cn = 610; ^dn = 611; ^en = 490; ^fn = 608. CZP certolizumab pegol, ITT intention-to-treat; RF rheumatoid factor, VAS visual analog scale, HAQ-DI health assessment questionnaire-disability index, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate

ISSN: 1478-6362